Clofazimine pharmacokinetics in novel rifampicin-resistant tuberculosis regimens: an analysis of the endTB and endTB-Q trials.

Ngara B, P Solans B, Yang E, Van Brantegem P, Guglielmetti L, Varaine F, Gouillou M, Mitnick CD, LaHood AN, Rich ML, Seung KJ, Wiesner L, Hans L, Swart R, Abubakirov A, Khazhidinov K, Belgozhanova A, Mpinda S, Mohale S, Holtzman D, Vargas Vasquez D, Garcia Velarde F, Mucching Toscano S, Aftab A, Arshad MS, Ashraf A, Luong DV, Nguyen HT, Phan HT, Wasserman S, Ntuli N, Savic R, McIlleron H, Velasquez GE

Open source

DOI: 10.64898/2026.09.18.26363422
Published: 2026 Sep 20
Container: medRxiv : the preprint server for health sciences
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.64898/2026.09.18.26363422,
  title = {Clofazimine pharmacokinetics in novel rifampicin-resistant tuberculosis regimens: an analysis of the endTB and endTB-Q trials.},
  author = {Ngara B and P Solans B and Yang E and Van Brantegem P and Guglielmetti L and Varaine F and Gouillou M and Mitnick CD and LaHood AN and Rich ML and Seung KJ and Wiesner L and Hans L and Swart R and Abubakirov A and Khazhidinov K and Belgozhanova A and Mpinda S and Mohale S and Holtzman D and Vargas Vasquez D and Garcia Velarde F and Mucching Toscano S and Aftab A and Arshad MS and Ashraf A and Luong DV and Nguyen HT and Phan HT and Wasserman S and Ntuli N and Savic R and McIlleron H and Velasquez GE},
  year = {2026},
  journal = {medRxiv : the preprint server for health sciences},
  doi = {10.64898/2026.09.18.26363422},
  url = {https://doi.org/10.64898/2026.09.18.26363422}
}

RIS

TY  - JOUR
TI  - Clofazimine pharmacokinetics in novel rifampicin-resistant tuberculosis regimens: an analysis of the endTB and endTB-Q trials.
AU  - Ngara B
AU  - P Solans B
AU  - Yang E
AU  - Van Brantegem P
AU  - Guglielmetti L
AU  - Varaine F
AU  - Gouillou M
AU  - Mitnick CD
AU  - LaHood AN
AU  - Rich ML
AU  - Seung KJ
AU  - Wiesner L
AU  - Hans L
AU  - Swart R
AU  - Abubakirov A
AU  - Khazhidinov K
AU  - Belgozhanova A
AU  - Mpinda S
AU  - Mohale S
AU  - Holtzman D
AU  - Vargas Vasquez D
AU  - Garcia Velarde F
AU  - Mucching Toscano S
AU  - Aftab A
AU  - Arshad MS
AU  - Ashraf A
AU  - Luong DV
AU  - Nguyen HT
AU  - Phan HT
AU  - Wasserman S
AU  - Ntuli N
AU  - Savic R
AU  - McIlleron H
AU  - Velasquez GE
PY  - 2026
JO  - medRxiv : the preprint server for health sciences
DO  - 10.64898/2026.09.18.26363422
UR  - https://doi.org/10.64898/2026.09.18.26363422
ER  -

APA

B, N., B, P. S., E, Y., P, V. B., L, G., F, V., M, G., CD, M., AN, L., ML, R., KJ, S., L, W., L, H., R, S., A, A., K, K., A, B., S, M., S, M., D, H., D, V. V., F, G. V., S, M. T., A, A., MS, A., A, A., DV, L., HT, N., HT, P., S, W., N, N., R, S., H, M., & GE, V. (2026). Clofazimine pharmacokinetics in novel rifampicin-resistant tuberculosis regimens: an analysis of the endTB and endTB-Q trials.. medRxiv : the preprint server for health sciences. https://doi.org/10.64898/2026.09.18.26363422

Source records

pubmed · retrieved 2026-09-25T08:42:57.548Z